Your browser doesn't support javascript.
loading
First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England.
Ladhani, Shamez N; Campbell, Helen; Andrews, Nick; Parikh, Sydel R; White, Joanne; Edelstein, Michael; Clark, Stephen A; Lucidarme, Jay; Borrow, Ray; Ramsay, Mary E.
Afiliação
  • Ladhani SN; Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
  • Campbell H; Paediatric Infectious Diseases Research Group (PIDRG), St George's University of London, London, United Kingdom.
  • Andrews N; Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
  • Parikh SR; Statistics, Modelling, and Economics Department, Public Health England, London, United Kingdom.
  • White J; Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
  • Edelstein M; Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
  • Clark SA; Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
  • Lucidarme J; Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
  • Borrow R; Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
  • Ramsay ME; Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
Clin Infect Dis ; 73(7): e1661-e1668, 2021 10 05.
Article em En | MEDLINE | ID: mdl-32845996
ABSTRACT

BACKGROUND:

4CMenB is a protein-based meningococcal B vaccine, but the vaccine antigens may be present on non-group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunization program, alongside an emergency adolescent meningococcal ACWY (MenACWY) program to control a national outbreak of group W (MenW) disease caused by a hypervirulent strain belonging to the ST-11 clonal complex. The adolescent program aimed to provide direct protection for adolescents and indirect protection across the population.

METHODS:

Public Health England conducts meningococcal disease surveillance in England. MenW cases confirmed during 4 years before and 4 years after implementation of both vaccines were analyzed. Poisson models were constructed to estimate direct protection against MenW disease offered by the infant 4CMenB program along with the indirect impact of the adolescent MenACWY program in children eligible for 4CMenB but not MenACWY.

RESULTS:

Model estimates showed 69% (adjusted incidence rate ratio [aIRR], .31; 95% CI, .20-.67) and 52% (aIRR, .48; 95% CI, .28-.81) fewer MenW cases than predicted among age-cohorts that were fully- and partly-eligible for 4CMenB, respectively. There were 138 MenW cases in <5-year-olds. 4CMenB directly prevented 98 (95% CI, 34-201) cases, while the MenACWY program indirectly prevented an additional 114 (conservative) to 899 (extreme) cases over 4 years. Disease severity was similar in 4CMenB-immunized and unimmunized children.

CONCLUSIONS:

This is the first real-world evidence of direct protection afforded by 4CMenB against MenWcc11 disease. 4CMenB has the potential to provide some protection against all meningococcal serogroups.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Meningocócicas / Infecções Meningocócicas / Neisseria meningitidis Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Child / Child, preschool / Humans / Infant País/Região como assunto: Europa Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Meningocócicas / Infecções Meningocócicas / Neisseria meningitidis Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Child / Child, preschool / Humans / Infant País/Região como assunto: Europa Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido